Study guide

4.3 Psychotic Disorders & Schizophrenia Spectrum

USMLE Step 2 CK Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Human Development & Well-Patient Care

1.1 Infant, Child & Adolescent Development & Growth 1.2 Adult Development, Aging & Geriatric Assessment 1.3 Preventive Health, Immunization & Well-Patient Screening

2 Chapter 2: Immune System & Immunologic Disorders

2.1 Primary & Secondary Immunodeficiencies 2.2 Hypersensitivity Reactions, Allergy & Anaphylaxis 2.3 Autoimmune & Rheumatologic Disease Principles

3 Chapter 3: Blood & Lymphoreticular System

3.1 Anemias: Microcytic, Normocytic & Macrocytic Etiologies 3.2 Bleeding Disorders, Coagulopathies & Platelet Pathology 3.3 Hematologic Malignancies & Lymphoproliferative Disorders

4 Chapter 4: Behavioral Health & Psychiatric Disorders

4.1 Mood Disorders: Major Depression & Bipolar Spectrum 4.2 Anxiety, Trauma-Related & Somatic Symptom Disorders 4.3 Psychotic Disorders & Schizophrenia Spectrum 4.4 Substance Use Disorders & Psychopharmacology

5 Chapter 5: Nervous System & Special Senses

5.1 Cerebrovascular Disease, Stroke & Transients 5.2 Seizures, Epilepsy & Altered Mental Status 5.3 Movement Disorders, Dementia & Peripheral Neuropathies 5.4 Special Senses: Ophthalmologic & Otolaryngologic Emergencies

6 Chapter 6: Musculoskeletal System & Dermatology

6.1 Fractures, Dislocations & Orthopedic Trauma 6.2 Inflammatory Arthropathies & Crystal-Induced Diseases 6.3 Inflammatory & Infectious Dermatoses 6.4 Cutaneous Malignancies & Blistering Disorders

7 Chapter 7: Cardiovascular System

7.1 Coronary Artery Disease & Acute Coronary Syndromes 7.2 Heart Failure, Cardiomyopathies & Valvular Disease 7.3 Cardiac Arrhythmias, Conduction Blocks & EKG Interpretation 7.4 Vascular Emergencies: Aortic Aneurysms & Peripheral Arterial Disease

8 Chapter 8: Respiratory System

8.1 Obstructive Airway Diseases: Asthma & COPD 8.2 Infectious Pneumonias & Pleural Effusions 8.3 Pulmonary Vascular Disease & Thromboembolism 8.4 Acute Respiratory Distress Syndrome & Interstitial Lung Diseases

9 Chapter 9: Gastrointestinal System

9.1 Esophageal, Gastric & Peptic Ulcer Disorders 9.2 Inflammatory Bowel Disease & Colorectal Neoplasms 9.3 Hepatic Disorders, Cirrhosis & Portal Hypertension 9.4 Biliary Tract Diseases & Pancreatitis

10 Chapter 10: Renal, Urinary & Reproductive Systems

10.1 Acute Kidney Injury & Chronic Kidney Disease 10.2 Glomerular & Tubulointerstitial Diseases 10.3 Nephrolithiasis, Urinary Tract Infections & Prostate Pathology 10.4 Fluid, Electrolyte & Acid-Base Disorders 10.5 Female Reproductive Disorders & Gynecology 10.6 Breast Pathology & Clinical Breast Disease

11 Chapter 11: Pregnancy, Childbirth & Puerperium

11.1 Normal Prenatal Care & Maternal-Fetal Physiology 11.2 Medical & Obstetric Complications of Pregnancy 11.3 Labor, Delivery & Postpartum Management

12 Chapter 12: Endocrine System

12.1 Diabetes Mellitus, Hypoglycemia & Metabolic Emergencies 12.2 Thyroid & Parathyroid Disorders 12.3 Adrenal & Pituitary Axis Pathology

13 Chapter 13: Multisystem Processes & Critical Care

13.1 Shock States, Sepsis & Systemic Inflammatory Response 13.2 Environmental Emergencies, Toxicology & Overdose 13.3 Infectious Disease Principles & Systemic Pathogens

14 Chapter 14: Biostatistics, Epidemiology & Literature Interpretation

14.1 Study Designs, Bias & Validity 14.2 Diagnostic Testing: Sensitivity, Specificity, PPV & NPV 14.3 Statistical Significance, Risk Measures & Evidence-Based Medicine

15 Chapter 15: Social Sciences, Ethics & Systems-Based Practice

15.1 Medical Ethics, Informed Consent & Patient Autonomy 15.2 Legal Issues, Confidentiality & Surrogate Decision Making 15.3 Patient Safety, Quality Improvement & Medical Error Analysis 15.4 Health Care Delivery Systems, Interprofessional Care & Transitions

4.3 Psychotic Disorders & Schizophrenia Spectrum

Key Takeaways Explain This Topic AI

Schizophrenia diagnosis requires continuous signs of disturbance for ≥6 months, including ≥1 month of active phase symptoms (at least 2 of: delusions, hallucinations, disorganized speech, grossly disorganized behavior, negative symptoms), with at least one being delusion, hallucination, or speech disorganization.

Psychotic spectrum disorders are differentiated by duration: Brief Psychotic Disorder (<1 month with full return to baseline), Schizophreniform Disorder (1 to 6 months), and Schizophrenia (>6 months).

Schizoaffective disorder requires ≥2 weeks of prominent hallucinations or delusions in the absence of a major mood episode, distinguishing it from mood disorders with psychotic features.

Clozapine is reserved for treatment-resistant schizophrenia (failure of ≥2 antipsychotic trials) or severe suicidality, requiring absolute neutrophil count (ANC) monitoring due to a 1% risk of agranulocytosis.

Second-generation antipsychotics (e.g., olanzapine, clozapine) carry high risk for metabolic syndrome (weight gain, dyslipidemia, hyperglycemia), requiring baseline and periodic lipid, fasting glucose, and BMI monitoring.

Last updated: July 2026

Pathophysiology & Dopaminergic Pathways of Psychosis

Psychotic spectrum disorders are characterized by abnormalities in one or more of five domains: delusions, hallucinations, disorganized thinking (speech), grossly disorganized or abnormal motor behavior (including catatonia), and negative symptoms. Neurochemically, psychosis is primarily linked to alterations in brain dopaminergic pathways.

Dopamine Pathway Physiology & Neuropharmacological Effects

Mesolimbic Pathway : Hyperactivity of dopamine transmission in this pathway causes positive symptoms (hallucinations, delusions, thought disorganization). Antipsychotics block D2 receptors here to reduce positive symptoms.

Mesocortical Pathway : Hypofunction of dopamine transmission causes negative symptoms (flat affect, avolition, alogia, asociality) and cognitive deficits. D2 blockade can potentially worsen negative symptoms.

Nigrostriatal Pathway : Part of the extrapyramidal motor system. D2 blockade leads to Extrapyramidal Symptoms (EPS) , including acute dystonia, akathisia, parkinsonism, and tardive dyskinesia.

Tuberoinfundibular Pathway : Dopamine tonically inhibits prolactin release from the anterior pituitary. D2 blockade disinhibits prolactin, causing hyperprolactinemia (galactorrhea, amenorrhea, gynecomastia, sexual dysfunction, bone mineral density loss).

Diagnostic Criteria for Schizophrenia Spectrum Disorders

To diagnose Schizophrenia , DSM-5 requires:

≥2 Active-Phase Symptoms present for a significant portion of time during a 1-month period (or less if successfully treated). At least one of these symptoms must be item 1, 2, or 3:

  • Delusions
  • Hallucinations (most commonly auditory)
  • Disorganized speech (e.g., frequent derailment or incoherence)
  • Grossly disorganized or catatonic behavior
  • Negative symptoms (diminished emotional expression or avolition)

Duration : Continuous signs of the disturbance must persist for at least 6 months . This 6-month period must include at least 1 month of active-phase symptoms and may include prodromal or residual periods.

Functional Impairment : Marked decline in work, interpersonal relations, or self-care relative to the level achieved prior to onset.

Time-Based Diagnostic Algorithm for Psychotic Spectrum Disorders Time-Based Diagnostic Flowchart for Psychosis:

1. Determine total duration of psychotic symptoms (delusions, hallucinations, disorganized speech/behavior):

- Duration <1 month with eventual full return to premorbid baseline -> Brief Psychotic Disorder.

- Duration 1 month to 6 months -> Schizophreniform Disorder.

- Duration >6 months (including prodromal, active phase ≥1 month, and residual phases) -> Schizophrenia.

2. Determine relationship between mood episodes (major depressive or manic) and psychotic symptoms:

- Psychotic symptoms occur EXCLUSIVELY during mood episodes -> Major Depressive or Bipolar Disorder with Psychotic Features.

- Psychotic symptoms present for ≥2 consecutive weeks in the ABSENCE of major mood episodes, but mood episodes are present for majority of total illness duration -> Schizoaffective Disorder.

3. Isolated non-bizarre or bizarre delusions for ≥1 month without other active schizophrenia symptoms -> Delusional Disorder.

Differential Diagnosis of Psychotic & Affective Disorders

Distinguishing psychotic disorders relies heavily on symptom timeline and mood symptom integration.

Antipsychotic Agent Generation Key Adverse Effect Profile Monitoring Requirements Clinical Indications

Haloperidol / Fluphenazine First (Typical) High risk of Extrapyramidal Symptoms (EPS), Tardive Dyskinesia, Hyperprolactinemia Neurologic exam, AIMS scale Acute agitation, severe positive symptoms

Olanzapine / Clozapine Second (Atypical) High risk of Metabolic Syndrome (weight gain, dyslipidemia, diabetes mellitus) Fasting lipids, glucose, HbA1c, BMI Psychosis; Clozapine for treatment-resistant disease

Clozapine Second (Atypical) Risk of Agranulocytosis (1%), Seizures, Myocarditis, Severe Constipation Absolute Neutrophil Count (ANC) weekly -> biweekly Refractory schizophrenia (≥2 failed trials), suicidality

Risperidone / Paliperidone Second (Atypical) Hyperprolactinemia (amenorrhea, galactorrhea, gynecomastia), moderate EPS Prolactin levels if symptomatic, AIMS scale Psychosis, pediatric bipolar/autism irritability

Ziprasidone Second (Atypical) Dose-dependent QTc prolongation, low metabolic risk Baseline ECG, serum potassium and magnesium Psychosis in patients at risk for weight gain

Aripiprazole Second (Atypical) Partial D2 agonist; Akathisia, lower metabolic and sedation risk Monitor for restlessness/akathisia Psychosis, bipolar maintenance, MDD augmentation

  • Antipsychotic Pharmacology & Adverse Effect Profiles
  • First-Generation (Typical) vs. Second-Generation (Atypical) Antipsychotics

First-Generation Antipsychotics (FGAs) (e.g., Haloperidol, Fluphenazine, Chlorpromazine): Potent D2 receptor antagonists. Highly effective for positive symptoms but carry significant risk of extrapyramidal side effects and tardive dyskinesia.

Second-Generation Antipsychotics (SGAs) (e.g., Olanzapine, Risperidone, Quetiapine, Aripiprazole, Clozapine): Dual 5-HT2A and D2 receptor antagonists. Serotonin blockade in the nigrostriatal pathway increases dopamine release, decreasing EPS risk. SGAs are first-line for schizophrenia, but carry variable risks for metabolic syndrome.

Clozapine Protocol & Refractory Schizophrenia

Clozapine is the most effective antipsychotic for schizophrenia. It is indicated for treatment-resistant schizophrenia (defined as failing ≥2 adequate trials of different antipsychotics, including at least one SGA) and for reducing suicidal behavior in schizophrenia. Major risks include:

Agranulocytosis : Potentially fatal neutropenia occurring in ~1% of patients. Mandatory blood monitoring of Absolute Neutrophil Count (ANC) is required: weekly for the first 6 months, biweekly for months 6–12, and monthly thereafter. Clozapine must be stopped if ANC drops below 1,000/mm³ (or <500/mm³ in benign ethnic neutropenia).

Seizures : Dose-dependent reduction in seizure threshold.

Myocarditis & Cardiomyopathy : Requires baseline ECG and monitoring of troponin/ESR if cardiac symptoms arise.

Severe Constipation / Paralytic Ileus : Due to potent anticholinergic activity.

Neurologic & Endocrine Complications of Antipsychotics

Acute Dystonia : Sudden, painful muscle contractions (e.g., torticollis, oculogyric crisis, opisthotonos) occurring hours to days after starting FGAs. Treatment: Intravenous or intramuscular Benztropine or Diphenhydramine .

Akathisia : Subjective feeling of inner restlessness and inability to sit still, occurring days to weeks after initiation. Treatment: Beta-blockers (Propranolol) (first-line), Lorazepam, or dose reduction.

Parkinsonism : Bradykinesia, resting tremor, cogwheel rigidity occurring weeks to months after starting antipsychotics. Treatment: Benztropine or Amantadine .

Tardive Dyskinesia (TD) : Involuntary choreoathetoid movements of the face, tongue, lips (orofacial dyskinesia), or extremities resulting from prolonged D2 blockade and receptor up-regulation (>6 months). Treatment: Discontinue FGA or switch to Clozapine/Quetiapine; administer VMAT2 inhibitors (Valbenazine, Deutetrabenazine) . Anticholinergic drugs may worsen TD.

Neuroleptic Malignant Syndrome (NMS) : Life-threatening hyperthermia, "lead-pipe" muscle rigidity, altered mental status, autonomic instability, and elevated serum creatine kinase (CK) and rhabdomyolysis. Treatment: Immediate drug withdrawal, aggressive cooling, IV fluids, and Dantrolene or Bromocriptine .